SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) May 17, 2004
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-23265 | 94-3267443 | |
(Commission file Number) | (IRS Employer ID Number) | |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
On May 17, 2004, Salix Pharmaceuticals, Ltd. announced that it will present at the UBS Global Specialty Pharmaceutical Conference in New York, NY on Monday, May 24.
Item 7. Financial Statements and Exhibits
(c) | Exhibits |
Exhibit 99.1 Press release dated May 17, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||
Date: May 17, 2004 | ||
/s/ Adam C. Derbyshire | ||
Adam C. Derbyshire | ||
Senior Vice President and Chief Financial Officer |